IP Library Granted Patent US 11,981,703
Granted Patent B2
US 11,981,703 · App. 16/326,542 · Granted May 14, 2024

Polynucleotide constructs

Inventors: Sukumar Sakamuri (San Diego, CA); Curt W. Bradshaw (San Diego, CA); Laxman Eltepu (San Diego, CA); Bryan R. Meade (San Diego, CA); Son Lam (San Diego, CA)
Assignee: SIRIUS THERAPEUTICS, INC.
C07H21/00C07F9/2408C07F9/65586C07F9/65616C07H21/02C07H21/04C12N15/113C12N15/85C12N2310/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,981,703
App. No.
16/326,542
Granted
May 14, 2024
Kind
B2
Abstract

Disclosed are polynucleotide constructs having a strand linked to a moiety carrying one or more auxiliary moieties. Also disclosed are polynucleotide constructs interrupted with a sugar analogue, and polynucleotide constructs with stereochemical{circumflex over ( )} enriched phosphorothioates. The polynucleotide constructs may be provided as hybridized polynucleotide constructs. Also featured are methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell by contacting the cell with the disclosed polynucleotide construct or hybridized polynucleotide construct.

Claims (15)

1. A polynucleotide construct or a salt thereof, comprising a linker conjugated to a polynucleotide and to a plurality of targeting moieties, wherein prior to conjugation of the targeting moieties, the linker has the structure X2,

and wherein conjugation of the targeting moieties to the linker occurs through one or more of the alkyne moieties of X2, and

wherein each of the targeting moieties comprises an N-acetyl galactosamine (GalNAc).

2. The polynucleotide construct of claim 1 , wherein prior to conjugation of the targeting moieties to the linker X2, the polynucleotide construct comprises a structure of

3. The polynucleotide construct of claim 1 , wherein the targeting moieties are selected from NAG26, NAG37, NAG38, and NAG39.

4. The polynucleotide construct of claim 1 , wherein prior to conjugation to the linker X2, each of the targeting moieties has the structure of

5. The polynucleotide construct of claim 1 , wherein the polynucleotide comprises a passenger strand and a guide strand.

6. The polynucleotide construct of claim 5 , wherein the X2 linker is bound to the passenger strand.

7. The polynucleotide construct of claim 6 , wherein the X2 linker is bound to the 3′-terminus of the passenger strand.

8. The polynucleotide construct of claim 5 , wherein the passenger strand is 15 to 32 nucleotides in length.

9. The polynucleotide construct of claim 5 , wherein the guide strand is 15 to 32 nucleotides in length.

10. The polynucleotide construct of claim 1 , wherein the X2 linker is conjugated with the targeting moieties by click reaction.

11. The polynucleotide construct of claim 1 , wherein the X2 linker comprises a terminal phosphotriester.

12. The polynucleotide construct of claim 11 , wherein the X2 linker is bound to a 3′ C 3 —OH group.

13. The polynucleotide construct of claim 1 , wherein the polynucleotide construct comprises one X2 linker.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2022
From: SOLSTICE BIOLOGICS LIMITED
To: CLEAR SKIES BIO LLC
Reel/Frame 060123/0004 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2022
From: SAKAMURI, SUKUMAR; BRADSHAW, CURT W.; ELTEPU, LAXMAN; MEADE, BRYAN R.; LAM, SON
To: SOLSTICE BIOLOGICS, LTD.
Reel/Frame 060123/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2022
From: CLEAR SKIES BIO LLC
To: SIRIUS THERAPEUTICS, INC.
Reel/Frame 060123/0482 →
Continuity (2)
Provisional Application 62376182 · Aug 17, 2016
Related Publication 20190202855A1 · Jul 4, 2019
Cited By (1)
US 12,269,839